Tag Archives: U.S.

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

Print this page ALAMEDA, Calif.–(BUSINESS WIRE)–Jan. 14, 2019– Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in… Read More »

J&J, U.S. states settle hip implant claims for $120 million

(Reuters) – Johnson & Johnson and its DePuy Orthopaedics unit have agreed to pay $ 120 million to resolve deceptive marketing claims by several U.S. states over the company’s metal-on-metal hip implants. FILE PHOTO: The Johnson and Johnson logo is seen at an office building in Singapore January 17, 2018. REUTERS/Thomas White/File Photo Attorneys general… Read More »